Advanced search
Publication Cover
Drug Metabolism Reviews Volume 53, 2021 - Issue 3
Submit an article Journal homepage
5,111
Views
4
CrossRef citations to date
0
Altmetric
Review Articles

Novel advances in biotransformation and bioactivation research – 2020 year in review

S. Cyrus Khojasteha Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8385-9288
ORCID Icon,
Upendra A. Argikarb Translational Medicine, Novartis Institutes for Biomedical Research, Inc., Cambridge, MA, USAORCID Iconhttps://orcid.org/0000-0002-0939-0813
ORCID Icon,
James P. Driscollc Department of Drug Metabolism and Pharmacokinetics, MyoKardia, Inc., South San Francisco, CA, USAORCID Iconhttps://orcid.org/0000-0002-3736-1673
ORCID Icon,
Carley J. S. Heckd Medicine Design, Pfizer Worldwide Research, Development and Medical, Groton, CT, USAORCID Iconhttps://orcid.org/0000-0002-6842-3670
ORCID Icon,
Lloyd Kinge Department of DMPK, UCB Biopharma, Slough, UKORCID Iconhttps://orcid.org/0000-0002-3301-7533
ORCID Icon,
Klarissa D. Jacksonf Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USAORCID Iconhttps://orcid.org/0000-0002-9388-9800
ORCID Icon,
Wenying Jiang Drug Metabolism and Pharmacokinetics, Janssen Research & Development, Spring House, PA, USAORCID Iconhttps://orcid.org/0000-0002-8731-981X
ORCID Icon,
Amit S. Kalgutkarh Medicine Design, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USAORCID Iconhttps://orcid.org/0000-0001-9701-756X
ORCID Icon,
Grover P. Milleri Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USAORCID Iconhttps://orcid.org/0000-0002-4743-8187
ORCID Icon,
Valerie Kramlingerb Translational Medicine, Novartis Institutes for Biomedical Research, Inc., Cambridge, MA, USAORCID Iconhttps://orcid.org/0000-0002-7237-164X
ORCID Icon,
Ivonne M. C. M. Rietjensj Division of Toxicology, Wageningen University, Wageningen, The NetherlandsORCID Iconhttps://orcid.org/0000-0003-1894-3544
ORCID Icon,
Aaron M. Teitelbaumk Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USAORCID Iconhttps://orcid.org/0000-0001-6737-0928
ORCID Icon,
Kai Wangl Drug Metabolism and Pharmacokinetics, Janssen Research & Development, San Diego, CA, USAORCID Iconhttps://orcid.org/0000-0002-9457-7534
ORCID Icon &
Cong Weim Drug Metabolism & Pharmacokinetics, Biogen Inc., Cambridge, MA, USA
 show all
Pages 384-433 | Received 08 Apr 2021, Accepted 08 Apr 2021, Published online: 24 Jun 2021

References

  • Baillie TA, Dalvie D, Rietjens IMCM, Khojasteh SC. 2016. Biotransformation and bioactivation reactions – 2015 literature highlights. Drug Metab Rev. 48(2):113–138.
  • Khojasteh SC, Bumpus NN, Driscoll JP, Miller GP, Mitra K, Rietjens IMCM, Zhang D. 2019. Biotransformation and bioactivation reactions – 2018 literature highlights. Drug Metab Rev. 51(2):121–161.
  • Khojasteh SC, Driscoll JP, Jackson KD, Miller GP, Mitra K, Rietjens IMCM, Zhang D. 2020. Novel advances in biotransformation and bioactivation research-2019 year in review. Drug Metab Rev. 52(3):333–365.
  • Khojasteh SC, Miller GP, Mitra K, Rietjens IMCM. 2018. Biotransformation and bioactivation reactions – 2017 literature highlights. Drug Metab Rev. 50(3):221–255.
  • Khojasteh SC, Rietjens IMCM, Dalvie D, Miller G. 2017. Biotransformation and bioactivation reactions – 2016 literature highlights. Drug Metab Rev. 49(3):285–317.

References

  • Gillis EP, Eastman KJ, Hill MD, Donnelly DJ, Meanwell NA. 2015. Applications of fluorine in medicinal chemistry. J Med Chem. 58:8315–8359.
  • Hu H, Katyayan KK, Czeskis BA, Perkins EJ, Kulanthaivel P. 2017. Comparison between radioanalysis and 19F nuclear magnetic resonance spectroscopy in the determination of mass balance, metabolism, and distribution of pefloxacin. Drug Metab Dispos. 45(4):399–408.
  • Kakutani N, Iwai T, Ohno Y, Kobayashi S, Nomura Y. 2021. Evaluation of covalent binding of flutamide and its risk assessment using 19F-NMR. Xenobiotica. 51(1):88–94.
  • Mei H, Remete AM, Zou Y, Moriwaki H, Fustero S, Kiss L, Soloshonok VA, Han J. 2020. Fluorine-containing drugs approved by the FDA in 2019. Chin Chem Lett. 31(9):2401–2413.
  • Pan Y. 2019. The dark side of fluorine. ACS Med Chem Lett. 10(7):1016–1019.
  • Wang J, Sanchez-Rosello M, Acena JL, Pozo C, Sorochinsky AE, Fustero S, Soloshonok VA, Liu H. 2013. Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001 − 2011). Chem Rev. 114:2432–2506.

References

  • Young GC, Croft M. 2020. AMS in drug development: exploring the current utility of AMS and future opportunities for absolute bioavailability and ADME investigations. In: Ma S and Chowdhury SK, editors. Identification and quantification of drugs, metabolites, drug metabolizing enzymes, and transporters. 2nd ed. Elsevier Science; p. 185–210.

References

  • Argikar UA, Potter PM, Hutzler JM, Marathe PH. 2016. Challenges and opportunities with non-CYP enzymes aldehyde oxidase, carboxylesterase, and UDP-glucuronosyltransferase: focus on reaction phenotyping and prediction of human clearance. AAPS J. 18(6):1391–1405.
  • Atilaw Y, Poongavanam V, Svensson Nilsson C, Nguyen D, Giese A, Meibom D, Erdelyi M, Kihlberg J. 2021. Solution conformations shed light on PROTAC cell permeability. ACS Med Chem Lett. 12(1):107–114.
  • Goracci L, Desantis J, Valeri A, Castellani B, Eleuteri M, Cruciani G. 2020. Understanding the metabolism of proteolysis targeting chimeras (PROTACs): the next step toward pharmaceutical applications. J Med Chem. 63(20):11615–11638.
  • Klein VG, Townsend CE, Testa A, Zengerle M, Maniaci C, Hughes SJ, Chan KH, Ciulli A, Lokey RS. 2020. Understanding and improving the membrane permeability of VH032-based PROTACs. ACS Med Chem Lett. 11 (9):1732–1738.
  • Lepper ER, Smith NF, Cox MC, Scripture CD, Figg WD. 2006. Thalidomide metabolism and hydrolysis: mechanisms and implications. Curr Drug Metab. 7(6):677–685.
  • Maple HJ, Clayden N, Baron A, Stacey C, Felix R. 2019. Developing degraders: principles and perspectives on design and chemical space. Medchemcomm. 10(10):1755–1764.
  • Pike A, Williamson B, Harlfinger S, Martin S, McGinnity DF. 2020. Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective. Drug Discov Today. 25(10):1793–1800.
  • Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. 2001. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci USA. 98(15):8554–8559.
  • Schumacher H, Smith RL, Williams RT. 1965. The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol Chemother. 25(2):338–351.
  • Wang Y, Jiang X, Feng F, Liu W, Sun H. 2020. Degradation of proteins by PROTACs and other strategies. Acta Pharm Sin B. 10(2):207–238.
  • Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E, Lin M, Liu L, Yang CY, Zhao Y, et al. 2018. Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J Med Chem. 61(2):462–481.
  • Zhou SF. 2008. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 9(4):310–322.
  • Zientek M, Jiang Y, Youdim K, Obach RS. 2010. In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos. 38(8):1322–1327.

References

  • Cerny MA, Kalgutkar AS, Obach RS, Sharma R, Spracklin DK, Walker GS. 2020. Effective application of metabolite profiling in drug design and discovery. J Med Chem. 63(12):6387–6406.
  • Fessner ND. 2019. P450 monooxygenases enable rapid late-stage diversification of natural products via C–H bond activation. ChemCatChem. 11(9):2226–2242.
  • Lall MS, Bassyouni A, Bradow J, Brown M, Bundesmann M, Chen J, Ciszewski G, Hagen AE, Hyek D, Jenkinson S, et al. 2020. Late-stage lead diversification coupled with quantitative nuclear magnetic resonance spectroscopy to identify new structure-activity relationship vectors at nanomole –scale synthesis: application to loratidine, a human histamine H1 receptor inverse agonist. J Med Chem. 63(13):7268–7292.
  • Shanu-Wilson J, Evans L, Wrigley S, Steele J, Atherton J, Boer J. 2020. Biotransformation: impact and application of metabolism in drug discovery. ACS Med Chem Lett. 11(11):2087–2107.
  • Walker GS, Bauman JN, Ryder TF, Smith EB, Spracklin DK, Obach RS. 2014. Biosynthesis of drug metabolites and quantitation using NMR spectroscopy for use in pharmacologic and drug metabolism studies. Drug Metab Dispos. 42(1):1627–1639.

References

  • de Bruyn Kops C, Šícho M, Mazzolari A, Kirchmair J. 2021. GLORYx: prediction of the metabolites resulting from phase 1 and phase 2 biotransformations of xenobiotics. Chem Res Toxicol. 34:286–299.
  • Judson PN. 2014. Knowledge-based approaches for predicting sites of and products metabolism, in drug metabolism prediction. p. 293–318. Weinheim, Germany: WIley-VCH.
  • Liu R, Liu J, Tawa G, Wallqvist A. 2012. 2D SMARTCyp reactivity-based site of metabolism prediction for major drug-metabolizing cytochrome P450 enzymes. Chem Inf Model. 52:1698–1712.
  • Pedretti A, Mazzolari A, Vistoli G, Testa B. 2018. MetaQSAR: an integrated database engine to manage and analyze metabolic data. J Med Chem. 61:1019–1030.
  • Ridder L, Wagener M. 2008. SyGMa: combining expert knowledge and empirical scoring in the prediction of metabolites. ChemMedChem. 3:821–832.
  • Šícho M, Stork C, Mazzolari A, de Bruyn Kops C, Pedretti A, Testa B, Vistoli G, Svozil D, Kirchmair J. 2019. FAME 3: predicting the sites of metabolism in synthetic compounds and natural products for phase 1 and phase 2 metabolic enzymes. J Chem Inf Model. 59:3400–3412.
  • Tomberg A, Pottel J, Liu Z, Labute P, Moitessier N. 2015. Understanding P450-mediated bio-transformations into epoxide and phenolic metabolites. Angew Chem Int Ed Engl. 54:13743–13747.
  • Wienkers LC, Heath TG. 2005. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov. 4:825–833.

References

  • Foti RS, Argikar UA. 2019. Uridine diphospho glucuronosyltransferases. In: Pearson PG, Weinkers LC, editors. Handbook of drug metabolism. 3rd ed. Boca Raton, FL: CRC Press; p. 109–159.
  • Korprasertthaworn P, Chau N, Nair PC, Rowland A, Miners JO. 2019. Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202. Biochem Pharmacol. 169:113616.
  • Miners JO, Plasek TM, Mackenzie PI, Knights KM. 2010. The in vitro characterization of inhibitory drug-drug interactions involving UDP-glucuronosyltransferase. In: Pang KS, Rodrigues AD, Peter R, editors. Enzyme and transporter based drug-drug interactions. New York: Springer; p. 217–236.
  • Miners JO, Chau N, Rowland A, Burns K, McKinnon RA, Mackenzie PI, Tucker GT, Knights KM, Kichenadasse G. 2017. Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: implications for hyperbilirubinemia. Biochem Pharmacol. 129:85–95.
  • Remmel RP, Zhou J, Argikar UA. 2008. UDP-glucuronosyltransferases. In: Rodrigues AD, editor. Drug-drug interactions. Drugs and the pharmaceutical sciences. Handbook of drug metabolism. Vol. 186. 2nd ed. Informa healthcare; p. 87–134.

References

  • Gant TG. 2014. Using deuterium in drug discovery; leaving the label in the drug. J Med Chem. 57(9):3595–3611.
  • Katsnelson A. 2013. Heavy drugs draw heavy interest from pharma backers. Nat Med. 19(6):656.
  • Miwa GT, Lu AYH. 1987. Kinetic isotope effects and ‘metabolic switching’ in cytochrome P450-catalyed reactions. BioEssays. 7(5):215–219.
  • Moslin R, Zhang Y, Wrobleski ST, Lin S, Mertzman M, Spergel S, Tokarski JS, Strnad J, Gillooly K, McIntyre KW, et al. 2019. Identification on N-methyl nicotinamide and N-methyl pyridazine-3-carboxamide pseudokinase domain ligands as highly selective allosteric inhibitors of tyrosine kinase 2 (TYK2). J Med Chem. 62(20):8953–8972.
  • Wrobleski ST, Moslin R, Lin S, Zhang Y, Spergel S, Kempson J, Tokarski JS, Strnad J, Zupa-Fernandez A, Cheng L, et al. 2019. Highly selective inhibition of tyrosine kinase (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 62(20):8973–8995.
  • Uttamsingh V, Gallegos R, Liu JF, Harbeson SL, Bridson GW, Cheng C, Wells DS, Graham PB, Zelle R, Tung R. 2015. Altering metabolic profiles of drugs by precision deuteration: reducing mechanism-based inhibition of CYP2D6 by paroxetine. J Pharmacol Exp Ther. 354(1):43–54.

References

  • Li J, Liu J, Enders J, Arciprete M, Tran C, Aluri K, Guan LH, O’Shea J, Bisbe A, Charisse K, et al. 2019. Discovery of a novel deaminated metabolite of a single-stranded oligonucleotide in vivo by mass spectrometry. Bioanalysis. 11(21):1955–1965.
  • Nair JK, Willoughby JLS, Chan A, Charisse K, Alam MR, Wang Q, Hoekstra M, Kandasamy P, Kel’in AV, Milstein S, et al. 2014. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 136(49):16958–16961.
  • Shen X, Corey DR. 2018. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res. 46(4):1584–1600.
  • Sutton JM, Kim J, El Zahar NM, Bartlett MG. 2020. Bioanalysis and biotransformation of oligonucleotide therapeutics by liquid chromatography-mass spectrometry. Mass Spectrom Rev. DOI:https://doi.org/10.1002/mas.21641.
  • Zlatev I, Castoreno A, Brown CR, Qin J, Waldron S, Schlegel MK, Degaonkar R, Shulga-Morskaya S, Xu H, Gupta S, et al. 2018. Reversal of siRNA-mediated gene silencing in vivo. Nat Biotechnol. 36(6):509–511.

References

  • Husser C, Brink A, Zell M, Muller MB, Koller E, Schadt S. 2017. Identification of GalNAc-conjugated antisense oligonucleotide metabolites using an untargeted and generic approach based on high resolution mass spectrometry. Anal Chem. 89(12):6821–6826.
  • Kim J, Basiri B, Hassan C, Punt C, van der Hage E, den Besten C, Bartlett MG. 2019. Metabolite profiling of the antisense oligonucleotide eluforsen using liquid chromatography-mass spectrometry. Mol Ther Nucleic Acids. 17:714–725.
  • Kim J, El Zahar NM, Bartlett MG. 2020. In vitro metabolism of 2’-ribose unmodified and modified phosphorothioate oligonucleotide therapeutics using liquid chromatography mass spectrometry. Biomed Chromatogr. 34(7):e4839.
  • Shen X, Corey DR. 2018. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res. 46(4):1584–1600.
  • Sutton JM, Kim J, El Zahar NM, Bartlett MG. 2020. Bioanalysis and biotransformation of oligonucleotide therapeutics by liquid chromatography-mass spectrometry. Mass Spectrom Rev. :1–25.

References

References

  • Guengerich FP, Munro AW. 2013. Unusual cytochrome P450 enzymes and reactions. J Biol Chem. 288(24):17065–17073.
  • Obach RS, Nedderman AN, Smith DA. 2012. Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary? Xenobiotica. 42(1):46–56.
  • Takahashi RH, Grander JM, Bobba S, Liu Y, Beroza P, Zhang D, Ma S. 2020. Novel homodimer metabolites of GDC-0994 via cytochrome P450-catalyzed radical coupling. Drug Metab Dispos. 48(6):521–527.

References

  • Ackermann EJ, Guo S, Benson MD, Booten S, Freier S, Hughes SG, Kim TW, Jesse Kwoh T, Matson J, Norris D, et al. 2016. Suppressing transhyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides. Amyloid. 23:148–157.
  • Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, et al. 2018. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 389:22–31.
  • Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, Matson J, Sasmor H, Cummins L, Levin AA. 2003. Pharmacokinetics of a tumor necrosis factor-α phosphorothionate 2’-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos. 31(11):1419–1428.
  • Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, Chuang E, Graham MJ, Crooke RM. 2006. Protein reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 114(16):1729–1735.
  • Pechlaner R, Tsimikas S, Yin X, Willeit P, Baig F, Santer P, Oberhollenzer F, Egger G, Witztum JL, Alexander VJ, et al. 2017. Very-low-density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III. J Am Coll Cardiol. 69(7):789–800.
  • Post N, Yu R, Greenlee S, Gaus H, Hurh E, Matson J, Wang Y. 2019. Metabolism and disposition of Volanesorsen, a 2'-O-(2 methoxyethyl) antisense oligonucleotide, across species. Drug Metab Dispos. 47:1164–1173.
  • Shen X, Corey DR. 2018. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res. 46:1584–1600.
  • Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS. 2007. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotides, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos. 35:460–468.

References

  • Tajima Y, Toyoda T, Hirayama Y, Matsushita K, Yamada T, Ogawa K, Watanabe K, Takamura-Enya T, Totsuka Y, Wakabayashi K, et al. 2020a. Novel o-toluidine metabolite in rat urine associated with urinary bladder carcinogenesis. Chem Res Toxicol. 33(7):1907–1914.
  • Tajima Y, Toyoda T, Hirayama Y, Matsushita K, Yamada T, Ogawa K, Watanabe K, Takamura-Enya T, Totsuka Y, Wakabayashi K, et al. 2020b. Correction to a novel o-toluidine metabolite in rat urine associated with urinary bladder carcinogenesis. Chem Res Toxicol. 33(12):3065–3065.

References

  • Arlt VM, Stiborova M, Schmeiser HH. 2002. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis. 17(4):265–277.
  • Arlt VM, Stiborová M, vom Brocke J, Simões ML, Lord GM, Nortier JL, Hollstein M, Phillips DH, Schmeiser HH. 2007. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis. 28(11):2253–2261.
  • Mengs U, Lang W, Poch JA. 1982. The carcinogenic action of aristolochic acid in rats. Arch Toxicol. 51(2):107–119.
  • Nortier JL, Vanherweghem JL. 2002. Renal interstitial fibrosis and urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). Toxicology. 181–182:577–580.
  • Schmeiser HH, Bieler CA, Wiessler M, deStrihou CV, Cosyns JP. 1996. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 56(9):2025–2028.
  • Vanhaelen M, Vanhaelenfastre R, But P, Vanherweghem JL. 1994. Identification of aristolochic acid in Chinese herbs. Lancet. 343(8890):174–174.
  • Vanherweghem J-L, Tielemans C, Abramowicz D, Depierreux M, Vanhaelen-Fastre R, Vanhaelen M, Dratwa M, Richard C, Vandervelde D, Verbeelen D, et al. 1993. Rapidly progressive interstitial renal fibrosis in young-women – association with slimming regimen including Chinese herbs. Lancet. 341(8842):387–391.
  • Zhang JY, Chan CK, Ham YH, Chan W. 2020. Identifying cysteine, N-acetylcysteine, and glutathione conjugates as novel metabolites of aristolochic acid I: emergence of a new detoxification pathway. Chem Res Toxicol. 33(6):1374–1381.

References

  • Aronson JK, editor 2016. Flufenamic acid and meclofenamic acid. Meyler's side effects of drugs. 16th ed. Oxford: Elsevier; p. 361.
  • Galati G, Tafazoli S, Sabzevari O, Chan TS, O’Brien PJ. 2002. Idiosyncratic NSAID drug induced oxidative stress. Chem Biol Interact. 142:25–41.
  • Gan J, Harper TW, Hsueh M-M, Qu Q, Humphreys WG. 2005. Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem. Res. Toxicol. 18(5):896–903.
  • Li Y, Qi XM, Xue X, Wu XF, Wu YF, Chen M, Xing GZ, Luan Y, Ren J. 2009. The relationship between diphenylamine structure and NSAIDs-induced hepatocytes injury. Toxicol Lett. 186:111–114.
  • Schleiff MA, Flynn NR, Payakachat S, Schleiff BM, Pinson AO, Province DW, Swamidass SJ, Boysen G, Miller GP. 2021. Significance of multiple bioactivation pathways for meclofenamate as revealed through modeling and reaction kinetics. Drug Metab Dispos. 49:133–141.
  • Wolfe MM, Lichtenstein DR, Singh G. 1999. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med. 340:1888–1899.

References

  • Castellino S, O’Mara M, Koch K, Borts DJ, Bowers GD, MacLauchlin C. 2012. Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity. Drug Metab Dispos. 40:139–150.
  • Korprasertthaworn P, Chau N, Nair PC, Rowland A, Miners JO. 2019. Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202. Biochem Pharmacol. 169:113616.
  • Miners JO, Chau N, Rowland A, Burns K, McKinnon RA, Mackenzie PI, Tucker GT, Knights KM, Kichenadasse G. 2017. Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: implications for hyperbilirubinemia. Biochem Pharmacol. 129:85–95.
  • Nardone-White DT, Bissada JE, Abouda AA, Jackson KD. 2021. Detoxication versus bioactivation pathways of lapatinib in vitro: UGT1A1 catalyzes the hepatic glucuronidation of debenzylated lapatinib. Drug Metab Dispos. 49(3):233–244.
  • US Food and Drug Administration. 2021. TykerbTM Clinical Pharmacology and Biopharmaceutics NDA Review. [accessed 2021 Feb 22]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022059s000_ClinPharmR.pdf.

References

  • Kalgutkar AS, Vaz AD, Lame ME, Henne KR, Soglia J, Zhao SX, Abramov YA, Lombardo F, Collin C, Hendsch ZS, et al. 2005. Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab Dispos. 33(3):243–253.
  • Kalgutkar AS. 2020. Designing around structural alerts in drug discovery. J Med Chem. 63(12):6276–6302.
  • Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, et al. 2021. Discovery of JNJ-63576253: a clinical stage androgen receptor antagonist for F877L mutant and wild-type castration-resistant prostate cancer (mCRPC). J Med Chem. 64(2):909–924.

References

  • Galati G, Tafazoli S, Sabzevari O, Chan TS, O’Brien PJ. 2002. Idiosyncratic NSAID drug induced oxidative stress. Chem Biol Interact. 142:25–41.
  • Gan J, Ma S, Zhang D. 2016. Non-P450 mediated drug bioactivation pathways and its toxicological relevance. Drug Metab. 48:473–501.
  • Grillo MP, Hua F, Knutson CG, Ware JA, Li C. 2003. Mechanistic studies on the bioactivation of diclofenac: Identification of diclofenac-S-acyl-glutathione in vitro in incubations with rat and human hepatocytes. Chem Res Toxicol. 16:1410–1417.
  • Li Y, Qi XM, Xue X, Wu XF, Wu YF, Chen M, Xing GZ, Luan Y, Ren J. 2009. The relationship between diphenylamine structure and NSAIDs-induced hepatocytes injury. Toxicol Lett. 186:111–114.
  • Mulder T, Bobba S, Johnson KM, Grandner JM, Wang W, Zhang C, Cai J, Choo EF, Khojasteh SC, Zhang D. 2020. Bioactivation of α,β-Unsaturated carboxylic acids through acyl-glucuronidation. Drug Metab Dispos. 48:819–829.

References

  • Kalgutkar AS, Vaz ADN, Lame ME, Henne KR, Soglia J, Zhao SX, Abramov YA, Lombardo F, Collin C, Hendsch ZS, et al. 2005. Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metabol Dispos. 33:243–253.
  • Pennington LD, Moustakas DT. 2017. The necessary nitrogen atom: a versatile high-impact design element for multiparameter optimization. J Med Chem. 60:3552–3579.
  • Zhang C, Crawford JJ, Landry ML, Chen H, Kenny JR, Khojasteh SC, Lee W, Ma S, Young WB. 2020. Strategies to mitigate the bioactivation of aryl amines. Chem Res Toxicol. 33(7):1950–1959.

References

  • Dalvie D, Kalgutkar AS, Chen W. 2015. Practical approaches to resolving reactive metabolite liabilities in early discovery. Drug Metab Rev. 47(1):56–70.
  • Ng W, Kennar R, Uetrecht J. 2014. Effect of clozapine and olanzapine on neutrophil kinetics: implications for drug-induced agranulocytosis. Chem Res Toxicol. 27(7):1104–1108.
  • Urban AE, Cubała WJ. 2017. Therapeutic drug monitoring of atypical antipsychotics. Psychiatr Pol. 51(6):1059–1077.

References

  • Bauman JN, Kelly JM, Tripathy S, Zhao SX, Lam WW, Kalgutkar AS, Obach RS. 2009. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and S-9 fraction. Chem Res Toxicol. 22(2):332–340.
  • Bell CC, Dankers ACA, Lauschke VM, Sison-Young R, Jenkins R, Rowe C, Goldring CE, Park K, Regan SL, Walker T, et al. 2018. Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study. Toxicol Sci. 162(2):655–666.
  • Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. 2004. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol. 17(1):3–16.
  • Kang W, Podtelezhnikov AA, Tanis KQ, Pacchione S, et al. 2020. Development and application of a transcriptomic signature of bioactivation in an advanced in vitro liver model to reduce drug-induced liver injury risk early in the pharmaceutical pipeline. Toxicol Sci. 177(1):121–139.
  • Monroe JJ, Tanis KQ, Podtelezhnikov AA, Nguyen T, et al. 2020. Application of a rat liver drug bioactivation transcriptional response assay early in drug development that informs chemically reactive metabolite formation and potential for drug-induced liver injury. Toxicol Sci. 177(1):281–299.
  • Mosedale M, Watkins PB. 2017. Drug-induced liver injury: advances in mechanistic understanding that will inform risk management. Clin Pharmacol Ther. 101(4):469–480.
  • Obach RS, Kalgutkar AS, Solgia JR, Zhao SX. 2008. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem Res Toxicol. 21(9):1814–1822.
  • Proctor WR, Foster AJ, Vogt J, Summer C, et al. 2017. Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. Arch Toxicol. 91(8):2849–2863.
  • Usui T, Mise M, Hashizume T, Yabuki M, Komuro S. 2009. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab Dispos. 37(12):2383–2392.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.